- Clearmind Medicine (CMND) has been granted patent approval from the Office of the Controller-General of Patents, Designs and Trademarks in India
- The patent refers to the company’s proprietary MEAI-based alcohol substitute patent family
- The company had also been earlier granted patents for this application in Europe and has pending applications in the United States and China for this patent family
- Clearmind is a biotech company focused on the discovery and development of safe and novel psychedelic-derived therapeutics to treat alcohol use disorder and other challenges
- Clearmind Medicine Inc. opened trading at $0.36 per share
Clearmind Medicine (CMND) has received patent approval from the Office of the Controller-General of Patents, Designs and Trademarks in India.
The patent refers to the company’s proprietary MEAI-based alcohol substitute patent family.
The company had also been earlier granted patents for this application in Europe and has pending applications in the United States and China for this patent family.
“Our innovation continues to gain global recognition, this time by the Indian patent office.” stated Adi Zuloff- Shani, Clearmind’s Chief Executive Officer.
“Clearmind is the sole owner of a family of patents concerning a synthetic substance as a replacement for alcohol, and we will address the tremendous global problem of alcohol abuse by developing both approved treatments and food supplements,” she added.
Clearmind is a new biotech company focused on the discovery and development of safe and novel psychedelic-derived therapeutics to treat alcohol use disorder and other pressing health challenges.
The Israeli-Canadian company holds several patents for the non-hallucinogenic compound MEAI (5-methoxy-2-aminoindane, a novel psychoactive substance).
The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Clearmind has established a research collaboration with the Hebrew University of Jerusalem and Bar Ilan University. The partnerships aim to expand its R&D capabilities and discover new candidate treatments for other mental health issues.
Clearmind Medicine Inc. opened trading at $0.36 per share.
